5 ASX Health stocks to add to your porfolio

5 ASX Health Stocks

Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about the industry’s future amidst changing interest rates. He compares the current market situation to 1994 when the introduction of interest rate tightenings led to bear markets for many pre-revenue stocks. However, despite ongoing mildly bearish market conditions since 2022, Stuart discussed on many stocks rallying ahead of potential peaks in interest rates.

The next Neuren Pharmaceuticals

Speaking on breakthroughs in the sector, Neuren Pharmaceuticals (ASX:NEU) is highlighted by Stuart for its strong progress, particularly with its drug to treat Rett syndrome, a severe autism spectrum disorder, leading to a significant increase in its stock value. Other promising ASX Health stocks mentioned include Actinogen (ASX:ACW), whose developing drug could potentially slow down cognitive decline in depression and Alzheimer’s patients, and Recce Pharmaceuticals (ASX:REH) who are working on a solution for antimicrobial resistance, an increasingly pressing issue in healthcare.

Stuart then brings attention to a few potential rising stars in the sector like Biotron Limited (ASX:BIT), another company targeting diseases prevalent in the ageing population such as Alzheimer’s. He provides further insights into companies like Immutep Limited (ASX:IMM), and Opthea Limited (ASX:OPT), which are making strides in cancer and eye disease treatments respectively. Stuart says the sector’s ongoing potential while urging investors to undertake diligent research due to the inherent risk associated with biotech stocks.

WATCH THE ENTIRE INTERVIEW HERE

What are the Best ASX Health Stocks to invest in right now?

Check our buy/sell tips